Immune checkpoint inhibitors (ICIs)-related ocular myositis

Immune check point inhibitors (ICIs) are a novel class of anti-tumor agents which have been linked to several neurological adverse event (irAE) including myositis (irMyositis), myocarditis and myasthenia.[1,2] Overlapping irMyositis with myocarditis or myasthenia has been reported in approximately 32% and 5% of cases respectively.[3] Conversely, while ocular involvement has been frequently observed in patients with generalized irMyositis and/or myasthenia, [4 –6] only few cases have been reported with isolated ocular myositis.

Source: Neuromuscular Disorders - February 25, 2020 Category: Neurology Authors: Matteo Garibaldi, Fabio Calabr ò, Gioia Merlonghi, Silvia Pugliese, Marco Ceccanti, Lara Cristiano, Tommaso Tartaglione, Antonio Petrucci Tags: Case report Source Type: research